Purchase up to 250 doses of MenveoR and pay only $81.37* per dose.
For Split shipments :
Not a CHA Member? Contact us to get signed up.
*Price does not include tax.
To receive this price on more than 250 doses, prior approval is needed. Contact your Novartis representative.
The 2013 recommended childhood and adolescent immunization schedules have been combined and approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the CDC, and the American Academy of Family Physicians. A new single schedule covering patients ages 0 to 18 was developed to overcome the growing complexity of the schedules and the need to provide more information on recommendations. Details are on the CDC Website .
GlaxoSmithKline (GSK) has started offering up front pricing to members who meet certain performance requirements. Members can now receive the lowest possible purchase price on GSK vaccines without having to wait for a rebate. To see if you qualify for this program, please contact a member of the Child Health Advantage team.
Beginning March 1, 2013, GlaxoSmithKline (GSK) will accept and fulfill orders for the Menveo vaccine manufactured by Novartis. This agreement will allow participants in the Child Health Advantage Program continued access to Menveo and will be included as part of the GSK agreement. If you have any questions regarding this offer, please feel free to contact any member of the Child Health Advantage Team.
If you have any questions regarding this offer, please feel free to contact any member of the Child Health Advantage Team.
A federal government advisory committee voted Tuesday to recommend that males ages 11 to 21 be vaccinated against the human papilloma virus, which is blamed for thousands of cases of cancer among women and men.
As of April 1, 2011, Child Health Advantage Members receive discounts up to 15% on Novartis' Menveo vaccine.
(Link to more info)
Novartis Receives Additional Approval for Menveo Vaccine
Novartis (Basel, Switzerland) received approval from the FDA (Silver Spring, MD) for the use of Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in individuals two to 10 years of age. The company received initial FDA approval in 2010 for use of Menveo in adolescents and adults from 11 to 55 years of age. (Read the full story).
The AAP's new vaccination recommendations target meningitis and whooping cough.
Teenagers need a booster shot to protect them from meningococcal meningitis, a potentially deadly infection of the tissue around the brain, while all kids should have up-todate whooping cough vaccines in light of recent outbreaks, according to new recommendations from pediatric experts.
The American Academy of Pediatrics issues updated vaccination guidelines annually. Its new schedule, released Feb. 1 in the journal Pediatrics, is very similar to last year's recommendations.
(Link to Complete Article).
Child Health Advantage is pleased to announce our exciting new partnership with Cardinal Health! Through our distribution agreement with Cardinal, CHA offers a whole new world of value to physician offices across the country.. Cardinal Health is a preferred distributor of medical/surgical, laboratory and pharmaceutical products that help physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability.
Cardinal Health is a single-source provider with a comprehensive offering through streamlined ordering, costs and workflow including:
The 2013 recommended childhood and adolescent vaccine schedules have been revised.
GlaxoSmithKline (GSK) has started offering up front pricing to members who meet certain performance requirements.
Beginning March 1, 2013, GlaxoSmithKline (GSK) will accept and fulfill orders for the Menveo vaccine manufactured by Novartis.